GenomeDx, Astellas deal

GenomeDx and Astellas partnered to identify prostate cancer patients undergoing active surveillance who may benefit from treatment with the pharma's Xtandi enzalutamide. Astellas will provide tumor samples from its ongoing Phase II ENACT trial, which is evaluating Xtandi vs. active surveillance. GenomeDx will use its Decipher Prostate Cancer Classifier test and Decipher Genomics Resource Information Database (GRID) to determine tumor aggressiveness. The companies declined to disclose financial terms...